Medicxi to invest $40m in D3 Bio.

Medicxi, a European life sciences investment firm, agreed to invest $40m in D3 Bio, a biotechnology company. "Our mission is to support the innovative genius of entrepreneurs by providing the critical capital, expertise and experience that form the all-important 'bridge' to pharma. George and his team are exceptional drug innovators focused on developing new treatments where there are enormous unmet patient and market needs," Francesco De Rubertis, Medicxi Co-founder and Partner.